Twitter Beğeni Hilesi

This was my first experience, and I’m thrilled with the outcome! I accomplished this while still in my final year of medical school. I’m committed to working even harder for greater achievements ahead

A systematic review and network meta-analysis of 20 RCTs with 14,995 mCSPC patients: ✅Darolutamide triplet (DARO + docetaxel + ADT) offers substantial OS benefits, particularly in high-burden patients. ✅Subgroup analyses indicate radical local therapy + ADT is optimal for

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Elisa Agostinetto 🇮🇹 Elisabetta Bonzano MD, PhD 🇮🇹 Luca Arecco, MD 🇮🇹 Gil Morgan, MD 🇺🇸 With our distinguished OncoAlert Faculty: Sara Tolaney

Dear Colleagues, OncoAlert 🚨is honoured to be covering #PROSCA24 #BLADDR24 & #RENALC24 for the Second Year REGISTER: ⭐️ prosca-bladdr.org/global-forum-o… ⭐️ Join our collaborators at Mirrors of Medicine this November 26-30, 2024 in Vienna Austria for 3 great back to back meetings on How New

Excited to share our commentary co-authored w/ Zeynep Irem Ozay, MD in Clinical Cancer Research highlighting the ph2 FUZE trial of Debio 1347 & the Rx landscape of FGFR-altered solid tumors! Thanks to the mentorship of Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer 👉tinyurl.com/3ca5b7sw👇 UroToday.com OncoAlert

Great summary: there will be some interesting work on potentially predictive markers presented at #ESMO24 Also food for discussion at Advanced Prostate Cancer Consensus Conference in 2025 and 2026!

A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05) out on ASTRO Practical Radiation Oncology practicalradonc.org/article/S1879-… The SBRT-Spanish 🇪🇸Group-05 trial (NCT02192788) is a multicenter, phase II

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dr Joseph McCollom DO 🇺🇸 Erman Akkus 🇹🇷 Gil Morgan, MD 🇺🇸 1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors

Dear Colleagues, The 🔟Day Countdown has officially Started for the #OncoAlert5k 🚨in Barcelona🇪🇸during #ESMO24 with over 💯 of our closest friends 🏃 🏃‍♀️ Runners Ready🎽 OncoAlert 🚨 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

Front row to watch Sumanta K. Pal, MD, FASCO ‘s terrific internal medicine grand round on gut bacteria and cancer! Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer Umang Swami Zeynep Irem Ozay, MD Georges Gebrael University of Utah Department of Internal Medicine Neli Ulrich, PhD Benjamin L Maughan Nicolas Sayegh, MD

The OncoAlert 🚨Newsletter NOW OUT Covering August 30- Sept5, 2024 Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TROPHY-U-01 #BladderCancer ✅DeLLphi-300🫁 SC #LungCancer ✅LITESPARK-013 #KidneyCancer ✅RADICALS-HD☢️ #ProstateCancer

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on The Lancet Oncology thelancet.com/journals/lanon… This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against

On behalf of International Urology Cancer Summit & the OncoAlert 🚨Network, extending a warm invitation to join us for the second International Urology Cancer Summit #IUCS24 HYBRID & FREE_‼️ September 27, 2024 in Portsmouth UK 🇬🇧 & ONLINE REGISTER: urologycancersummit.org/registration/

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on The Lancet Oncology thelancet.com/journals/lanon… This phase 3 randomized controlled trial (CCTG HE1) aimed to

My TOP 10 #GU ESMO - Eur. Oncology abstracts for #ESMO24 1/ 3

2/3

3/3

Introducing the CHIEF model for cancer diagnosis! A breakthrough in AI for histopathology, CHIEF extracts diverse imaging features and shows up to 36.1% better performance across populations. This could revolutionize cancer subtype classification and prognosis. #AI